Author's response to reviews

Title: Preclinical and clinical phase I studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen(R).

Authors:

Davide Crobu (davide.crobu@multimedica.it)
Gaia Spinetti (gaia.spinetti@multimedica.it)
Rodolfo Schrepfer (rodolfo.schrepfer@multimedica.it)
Giancarlo Tonon (giancarlo.tonon@multimedica.it)
Gloria Saccani Jotti (gloria.saccani@unipr.it)
Pierluigi Onali (onali@unica.it)
Simona Dedoni (dedoni@unica.it)
Gaetano Orsini (orsini.g@libero.it)
Andrea Di Stefano (andrea.distefano@croalliance.com)

Version: 3 Date: 21 January 2014

Author's response to reviews: see over
To the Editors of the
BMC Pharmacology and Toxicology

Pula, January 21th, 2014

Dear Sirs,

attached please find the manuscript by Crobu et al., entitled “Preclinical and clinical phase I studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen®” with the following amendments as requested by the Referees and Editor in date December 30th 2013:

Referee A:
1. Background-abstract: confirmation of CD34 mobilization as primary purpose using G-CSF (page 1)
2. Amendment of table 6 with more information (page 20)

Referee B:
1. see point 1 above.
2. Use of G-CSF in coronary disease and neurogenesis.
   This statement has been moved from Conclusions to Background in agreement with the referee’s observation since the use of G-CSF in coronary disease and neurogenesis is an evidence under investigation.
3. Discussion regarding the ability of BK0023 in comparison with Neupogen in CD34 mobilization (page 21).
4. Specification of Binding Analysis Program used (page 16).
Additional amendments are described here below:

1. English editing.
2. Figure’s legends have been amended in order to improve the reading and understanding.
3. Competing interest (before to References).
4. Acknowledgment (before to References).

We thank you very much for the consideration.

Looking forward to hearing from you.

Best regards.

Dr. Davide Crobu
(Corresponding author)

Address: Bioker srl, c/o Sardinia Scientific and Technological Park, Building 3, 09010 Pula (Cagliari), Italy
Tel. +39 070 9243 3183; fax +39 070 9243 3181
Email: davide.crobu@multimedica.it